Health
Results: 6757-6768 of 8097

Nordic Bioscience to make its precision medicine biomarker PRO-C3 available in China for research use only (RUO) in the first quarter of 2024.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile







